Background alzheimers Shape Background alzheimers Shape Background alzheimers Shape
Grants > Rational Design of Amyloid Beta-Protein Aggregation and Toxicity Inhibitors Updated On: Ene. 19, 2025
Alzheimer's Disease Research Grant

Rational Design of Amyloid Beta-Protein Aggregation and Toxicity Inhibitors

Principal Investigator

Gal Bitan, PhD

University of California, Los Angeles

Los Angeles, CA, USA

About the Research Project

Program

Alzheimer's Disease Research

Award Type

Pilot

Award Amount

$100,000

Active Dates

April 01, 2008 - March 31, 2010

Grant ID

A2008350

Goals

In this project we will use a novel approach that combines our most current understanding of the molecular processes that lead to AD. We do that by “tailoring” sophisticated weapons that target what is believed to be the very first event along the pathway that leads to formation of the toxic molecules that rob AD patients of their memory and personality.

Summary

Alzheimer’s disease (AD) is a current major public health threat, which despite tremendous research efforts, to date has no cure. To cure and prevent the disease we must invent drugs that treat the root of the problem. In this project we will use a novel approach that combines our most current understanding of the molecular processes that lead to AD. We do that by “tailoring” sophisticated weapons that target what is believed to be the very first event along the pathway that leads to formation of the toxic molecules that rob AD patients of their memory and personality. Unlike the direction used by most pharmaceutical companies – screening of large, random collections of molecules,our study is the first example of using a rational-design approach that is based on the three-dimensional structure of the toxic protein that causes AD.